Program
Nuvastatic
Also written as “Nuvastatic™” and “Nuvastatic ™”.
Its studies are mostly in Fatigue · Breast Neoplasms · Diabetic Retinopathy · COVID-19, led by Natureceuticals Sdn Bhd.
Furthest: phase 3, since Dec 23, 20254 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Natureceuticals Sdn Bhd | 41 open or running | phase 3since Dec 23, 2025 | Sep 5, 2020 | Mar 31, 2027phase 3 · NCT07669519 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2020First study: phase 2 study in Diabetic RetinopathyFirst studyNCT04552600 · 100 enrolled · India
- Sep 6, 2020Phase 1 study in COVID-19NCT04542447 · 10 enrolled · India
- Dec 23, 20252 phase 3 studiesPhase 3 reachedNCT07669519, NCT07669506
Ahead
- Mar 31, 2027Primary completion: phase 3 study in FatigueNCT07669519
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07669519Fatigue · India | 3 | Recruiting | Mar 31, 2027 | 180 |
| NCT07669506Breast Neoplasms · India | 3 | Completed | Apr 25, 2026 | 180 |
| NCT04542447COVID-19 · India | 1 | UNKNOWN | Sep 30, 2020 | 10 |
| NCT04552600Diabetic Retinopathy · India | 2 | Completed | Aug 10, 2022 | 100 |
How it is read
Names in the registry
- “Nuvastatic”, 2 entries
- “Nuvastatic™”, 1 entry
- “Nuvastatic ™”, 1 entry
Conditions, from the studies’ own filings
- Fatigue, 1 study
- Breast Neoplasms, 1 study
- Diabetic Retinopathy, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.